Overcoming hurdles to development of a vaccine against Pneumocystis jirovecii

Research output: Contribution to journalComment/debate

2 Scopus citations


Development of Pneumocystis pneumonia (PCP) is a common problem among immunosuppressed individuals. There are windows of opportunity in which vaccination would be beneficial, but to date, no vaccines have made it to clinical trials. Significant hurdles to vaccine development include host range specificity, making it difficult to translate from animal models to humans. Discovery of crossreactive epitopes is critical to moving vaccine candidates from preclinical animal studies to clinical trials.

Original languageEnglish
Article numbere00035-17
JournalInfection and Immunity
Issue number4
StatePublished - Apr 1 2017

Bibliographical note

Funding Information:
This work was supported in part by grant AI118818 from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, U.S. Department of Health and Human Services.

Publisher Copyright:
© 2017 American Society for Microbiology.


  • Pneumocystis carinii
  • Vaccines

ASJC Scopus subject areas

  • Parasitology
  • Microbiology
  • Immunology
  • Infectious Diseases


Dive into the research topics of 'Overcoming hurdles to development of a vaccine against Pneumocystis jirovecii'. Together they form a unique fingerprint.

Cite this